A5058637456- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Retinal Imaging and Analysis
- Glaucoma and retinal disorders
Rigshospitalet
2016-2025
University of Copenhagen
2014-2018
Glostrup Hospital
2014
To report short-term outcomes of treatment switch to faricimab in real-world patients with aflibercept-resistant neovascular age-related macular degeneration (AMD).
To investigate long-term functional and anatomical outcomes, discontinuation patterns, drug switching rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national guidelines. Retrospective cohort study 566 eyes centre-involved DME who started intravitreal treatment between January 2011 December 2013 Greater Copenhagen region. Data were retrieved from a database patient records March 2016 analysed...
To characterize frequency, morphological cause and time-dependent change of boundary line artefacts in optical coherence tomography (OCT) examinations centre-involved diabetic macular oedema (ciDME) patients who underwent ranibizumab treatment with 1-year follow-up to evaluate the impact on retinal thickness. One hundred fourteen were examined radial scan protocol by Topcon 3D OCT at baseline, 3 12 months. All B scans from all visits for (artefacts) stratified element causing including hard...
Some patients with neovascular age-related macular degeneration (nAMD) do not respond to anti-VEGF treatment or develop tolerance tachyphylaxis. If optimal response is lacking a given drug, switching another common practice. The aim of this study was report short-term outcomes switch faricimab in real-world nAMD resistant both aflibercept and ranibizumab. Single-center, retrospective cohort study. Chart-review 13 eyes multi-switch using electronic injection database, medical records, optical...
To quantify the fluid resorption from centre of fovea in a pregnant woman with diabetic macular oedema by daily optical coherence tomography (OCT) measurements after administration intravitreal dexamethasone implant (Ozurdex® ).A 36-year-old type 1 diabetes for 33 years presented foveal serous detachment and symptomatic vision loss at 16 gestational weeks. Best-corrected visual acuity (BCVA) Snellen notation central retinal volume assessed (OCT, Topcon Corporation) were measured almost on...